help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kraenzlin, M. E.
Right arrow Articles by Baylink, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kraenzlin, M. E.
Right arrow Articles by Baylink, D. J.

Journal of Clinical Endocrinology & Metabolism, Vol 71, 442-451, Copyright © 1990 by Endocrine Society


ARTICLES

Development of an immunoassay for human serum osteoclastic tartrate- resistant acid phosphatase

ME Kraenzlin, KH Lau, L Liang, TK Freeman, FR Singer, J Stepan and DJ Baylink
Department of Medicine, Loma Linda University, California.

A tartrate-resistant acid phosphatase (TrACP), which has been suggested to be very similar to the osteoclastic TrACP, was partially purified from the spleen of a patient with hairy cell leukemia. The purification procedure consisted of carboxymethyl-Sepharose, phosphocellulose, Sephacryl S-200, and phenyl-Sepharose chromatographies. Polyclonal antibodies were generated in guinea pigs with a titer of at least 1:6000. Immunohistochemical staining of fetal rat tibia with the antisera revealed that only the lysosomes of osteoclasts, but not osteoblasts, were stained. An enzyme-linked immunosorbent assay (ELISA) was developed with the antisera. There was no cross-reactivity with 1) partially purified acid phosphatases (ACPs) from normal human and beef spleens, 2) ACPs in extracts of human osteoblastic cells, 3) purified bovine bone matrix TrACP, or 4) commercial prostatic ACP. However, extracts of giant cell bone tumors, containing large amounts of bona fide osteoclasts, showed large amounts of cross-reactive material, which diluted in parallel with the partially purified hairy cell leukemic TrACP in the ELISA. Commercial serum band 5b TrACP also displaced in parallel with the partially purified hairy cell leukemic TrACP. Immunoblotting studies revealed that the antiserum, but not nonimmune guinea pig serum, reacted with the homogeneous hairy cell leukemia splenic band 5 TrACPs, which were recently purified by our laboratory. Preliminary application of the ELISA to sera of patients with metabolic bone diseases revealed that normal healthy individuals had measurable amounts of the immunoreactive material, and patients with Paget's disease or hyperparathyroidism, who should have high bone turnover, had elevated levels of this immunoreactive material in their sera. In contrast, the level of serum osteoclastic TrACP in a patient with an acute lymphatic leukemia was normal. In summary, 1) we have shown that hairy cell leukemia splenic TrACP shares significant immunological similarity with the osteoclastic TrACP and with the serum band 5b TrACP, and 2) the ELISA holds promise for a sensitive and specific assay for bone resorption.


This article has been cited by other articles:


Home page
IBMS BoneKEyHome page
M. E. Kraenzlin
Biochemical Markers of Bone Turnover and Osteoporosis Management
IBMS BoneKEy, July 1, 2007; 4(7): 191 - 203.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. Fohr, C. R. Dunstan, and M. J. Seibel
Markers of Bone Remodeling in Metastatic Bone Disease
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5059 - 5075.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
E Dogan and C Posaci
Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women
Postgrad. Med. J., December 1, 2002; 78(926): 727 - 731.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
A. J. Janckila, K. Takahashi, S. Z. Sun, and L. T. Yam
Tartrate-resistant Acid Phosphatase Isoform 5b as Serum Marker for Osteoclastic Activity
Clin. Chem., January 1, 2001; 47(1): 74 - 80.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
Y. R. Nakasato, A. J. Janckila, J. M. Halleen, H. K. Vaananen, S. P. Walton, and L. T. Yam
Clinical Significance of Immunoassays for Type-5 Tartrate-resistant Acid Phosphatase
Clin. Chem., December 1, 1999; 45(12): 2150 - 2157.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. M. Halleen, S. Raisanen, J. J. Salo, S. V. Reddy, G. D. Roodman, T. A. Hentunen, P. P. Lehenkari, H. Kaija, P. Vihko, and H. K. Vaananen
Intracellular Fragmentation of Bone Resorption Products by Reactive Oxygen Species Generated by Osteoclastic Tartrate-resistant Acid Phosphatase
J. Biol. Chem., August 13, 1999; 274(33): 22907 - 22910.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M. Nakanishi, K. Yoh, K. Uchida, S. Maruo, and A. Matsuoka
Improved method for measuring tartrate-resistant acid phosphatase activity in serum
Clin. Chem., February 1, 1998; 44(2): 221 - 225.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society